^
Association details:
| Biomarker: | SPRED2 deletion |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERa-Positive Breast Cancer
Published date:
02/14/2022
Excerpt:
Treatment of SPRED2-deficient breast cancer cells with a combination of the ERK 1/2 inhibitor ulixertinib and 4-hydroxytamoxifen (4-OHT) can inhibit cell growth and proliferation and overcome the induced tamoxifen resistance. Taken together, these results indicate that SPRED2 may also be a tumor suppressor for breast cancer and that it is a key regulator of cellular sensitivity to 4-OHT.
Secondary therapy:
afimoxifene
DOI:
https://doi.org/10.3390/cancers14040954
